Table 3.
Insulin resistance change in 26 active rheumatoid arthritis patients exposed to biologics by tofacitinib therapy
|
Group
|
Before
|
After
|
P
value1
|
| All (n = 26) | |||
| DAS28 | 5.265 ± 0.547 (4.54-6.74) | 3.051 ± 0.516 (2.11-3.99) | < 0.001 |
| Decrease in DAS28 | 2.214 ± 0.688 (1.08-3.49) | ||
| HOMA-IR | 2.548 ± 0.925 (1.33-4.75) | 2.251 ± 1.067 (0.85-4.55) | 0.016 |
| QUICKI | 0.3358 ± 0.0177 (0.305-0.366) | 0.3446 ± 0.0242 (0.305-0.394) | 0.016 |
| High IR (n = 19) | |||
| DAS28 | 5.316 ± 0.807 (4.63-6.74) | 3.070 ± 0.466 (2.42-3.90) | < 0.001 |
| Decrease in DAS28 | 2.246 ± 0.672 (1.08-3.49) | ||
| HOMA-IR | 2.924 ± 0.790 (2.10-4.75) | 2.545 ± 1.080 (1.05-4.55) | 0.018 |
| QUICKI | 0.3273 ± 0.0117 (0.305-0.341) | 0.3372 ± 0.0214 (0.305-0.380) | 0.008 |
| Low IR (n = 7) | |||
| DAS28 | 5.124 ± 0.332 (4.54-5.48) | 3.000 ± 0.672 (2.11-3.99) | 0.016 |
| Decrease in DAS28 | 2.124 ± 0.778 (1.25-3.33) | ||
| HOMA-IR | 1.527 ± 0.159 (1.33-1.77) | 1.453± 0.478 (0.85-2.18) | 0.781 |
| QUICKI | 0.3589 ± 0.0059 (0.350-0.366) | 0.3648 ± 0.0204 (0.340-0.394) | 0.813 |
1
Before vs after TOF therapy.
HOMA-IR: Homeostatic model assessment-insulin resistance; QUICKI: Quantitative Insulin Sensitivity Check Index; TOF: Tofacitinib; DAS28: Disease Activity Score 28.